Sareum Holdings PLC - Cambridge, England-based drug discovery and development - Notes the announcement by UK Department of Health & Social Care regarding the launch of Agile clinical development platform to fund phase 1 trials and fast-track the development of Covid-19 treatments. Company views this new platform as a welcome source of funding to support the early clinical development of promising new candidates to address the breadth of symptoms that affect patients with Covid-19. Sareum is currently investigating SDC-1801, a selective, small molecule TYK2/JAK1 kinase inhibitor, in a preclinical Covid-19 research programme.
"We are delighted that the UK government has created the Agile clinical trial platform and has provided the funding needed to support this exciting and much needed initiative, which may represent a potential route of future funding for the company," said Chief Scientific Officer John Reader.
Current stock price: 2.04 pence
Year-to-date change: down 16%
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Sareum (SAR)